Arbutus Biopharma Corporation (ABUS)
Largest Insider Buys in Sector
ABUS Stock Price History Chart
ABUS Stock Performance
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid …
Insider Activity of Arbutus Biopharma Corporation
Over the last 12 months, insiders at Arbutus Biopharma Corporation have bought $0 and sold $111,487 worth of Arbutus Biopharma Corporation stock.
On average, over the past 5 years, insiders at Arbutus Biopharma Corporation have bought $0 and sold $509,906 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.
List of Insider Buy and Sell Transactions, Arbutus Biopharma Corporation
| 2024-08-14 | Sale | director | 8,846 0.0048% | $3.69 | $32,637 | 0.00% | ||
| 2024-02-02 | Sale | Interim President & CEO | 10,164 0.0057% | $2.31 | $23,504 | +40.55% | ||
| 2024-02-02 | Sale | Chief Scientific Officer | 9,982 0.0056% | $2.31 | $23,083 | +40.55% | ||
| 2024-02-02 | Sale | Chief Financial Officer | 9,593 0.0054% | $2.31 | $22,184 | +40.55% | ||
| 2024-02-02 | Sale | Chief Medical Officer | 4,358 0.0024% | $2.31 | $10,078 | +40.55% | ||
| 2021-12-01 | Sale | Chief Scientific Officer | 200,000 0.218% | $5.09 | $1.02M | -44.14% | ||
| 2021-02-09 | Sale | Chief Business Officer | 20,000 0.0239% | $5.00 | $100,000 | -25.28% | ||
| 2020-12-14 | Sale | Chief Business Officer | 40,000 0.0439% | $5.00 | $200,032 | -29.51% | ||
| 2020-07-23 | Sale | Chief Business Officer | 20,000 0.0203% | $5.01 | $100,200 | -46.45% | ||
| 2018-08-13 | Sale | Chief Scientific Officer | 4,250 0.0076% | $9.51 | $40,436 | -60.00% | ||
| 2018-07-11 | Sale | Chief Scientific Officer | 10,000 0.017% | $10.00 | $100,000 | -61.98% | ||
| 2018-07-09 | Sale | Chief Scientific Officer | 10,000 0.0183% | $8.91 | $89,060 | -53.41% | ||
| 2018-07-06 | Sale | Chief Scientific Officer | 10,000 0.0166% | $8.45 | $84,500 | -55.27% | ||
| 2018-07-05 | Sale | Chief Scientific Officer | 10,000 0.0167% | $8.40 | $84,000 | -54.73% | ||
| 2018-07-03 | Sale | Chief Scientific Officer | 10,000 0.0174% | $8.00 | $80,000 | -50.24% | ||
| 2017-10-03 | Sale | Chief Scientific Officer | 20,000 0.0392% | $8.00 | $160,000 | -21.85% | ||
| 2017-08-15 | Sale | Chief Scientific Officer | 60,000 0.1079% | $3.70 | $222,000 | +51.33% | ||
| 2015-08-24 | director | 2,000 0.004% | $6.95 | $13,900 | -39.25% |
Insider Historical Profitability
| HENRIQUES RICHARD C JR | director | 1000 0.0005% | $3.21 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Whitefort Capital Management Lp | $33.18M | 6.82 | 12.86M | -2.54% | -$864,067.80 | 21.68 | |
| BlackRock | $26.84M | 5.51 | 10.4M | +0.14% | +$36,943.02 | <0.01 | |
| Morgan Stanley | $22.78M | 4.68 | 8.83M | +26.43% | +$4.76M | <0.01 | |
| Kairos Capital Management Lp | $20.23M | 4.16 | 7.84M | -13.27% | -$3.1M | 9.69 | |
| The Vanguard Group | $15.45M | 3.17 | 5.99M | -0.02% | -$2,518.08 | <0.0001 |